Contineum Therapeutics to Attend Upcoming Investor Conferences
Contineum Therapeutics (NASDAQ: CTNM), a clinical stage biopharmaceutical company developing oral small molecule therapies for neuroscience, inflammation and immunology conditions, has announced its participation in two major investor conferences in November 2024.
The company will attend the Stifel 2024 Healthcare Conference in New York on November 18, where CEO Carmine Stengone will present at 4:10 p.m. ET. Additionally, management will participate in one-on-one meetings at the Jefferies 2024 London Healthcare Conference on November 21. The Stifel presentation will be available via webcast on Contineum's website with replay access.
Contineum Therapeutics (NASDAQ: CTNM), una compagnia biofarmaceutica in fase clinica che sviluppa terapie a base di piccole molecole orali per condizioni di neuroscienza, infiammazione e immunologia, ha annunciato la sua partecipazione a due importanti conferenze per investitori a novembre 2024.
La compagnia parteciperà alla Stifel 2024 Healthcare Conference a New York il 18 novembre, dove il CEO Carmine Stengone presenterà alle 16:10 ET. Inoltre, il management parteciperà a incontri individuali alla Jefferies 2024 London Healthcare Conference il 21 novembre. La presentazione di Stifel sarà disponibile in diretta streaming sul sito web di Contineum con accesso alla registrazione.
Contineum Therapeutics (NASDAQ: CTNM), una empresa biofarmacéutica en etapa clínica que desarrolla terapias orales de moléculas pequeñas para condiciones de neurociencia, inflamación e inmunología, ha anunciado su participación en dos importantes conferencias para inversores en noviembre de 2024.
La compañía asistirá a la Stifel 2024 Healthcare Conference en Nueva York el 18 de noviembre, donde el CEO Carmine Stengone presentará a las 4:10 p.m. ET. Además, la dirección participará en reuniones one-on-one en la Jefferies 2024 London Healthcare Conference el 21 de noviembre. La presentación de Stifel estará disponible a través de una transmisión web en el sitio web de Contineum con acceso a la repetición.
Contineum Therapeutics (NASDAQ: CTNM), 신경과학, 염증 및 면역학적 질환을 위한 경구 소분자 치료제를 개발하는 임상 단계의 바이오제약 회사가 2024년 11월에 두 주요 투자자 회의에 참석한다고 발표했습니다.
회사는 11월 18일 뉴욕에서 열리는 Stifel 2024 Healthcare Conference에 참석하며, CEO Carmine Stengone는 오후 4시 10분(ET)에 발표할 예정입니다. 또한, 경영진은 11월 21일에 열리는 Jefferies 2024 London Healthcare Conference에서 일대일 미팅에 참여합니다. Stifel 발표는 Contineum의 웹사이트를 통해 웹캐스트로 제공되며 재생 접근이 가능합니다.
Contineum Therapeutics (NASDAQ: CTNM), une entreprise biopharmaceutique en phase clinique développant des thérapies orales à petites molécules pour des conditions en neurosciences, inflammation et immunologie, a annoncé sa participation à deux grandes conférences pour investisseurs en novembre 2024.
L'entreprise assistera à la Stifel 2024 Healthcare Conference à New York le 18 novembre, où le PDG Carmine Stengone interviendra à 16h10 ET. De plus, la direction participera à des réunions individuelles lors de la Jefferies 2024 London Healthcare Conference le 21 novembre. La présentation de Stifel sera disponible en streaming sur le site de Contineum, avec accès à une rediffusion.
Contineum Therapeutics (NASDAQ: CTNM), ein biopharmazeutisches Unternehmen in der klinischen Phase, das orale kleine Molekültherapien für neurologische, entzündliche und immunologische Erkrankungen entwickelt, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im November 2024 bekannt gegeben.
Das Unternehmen wird am 18. November an der Stifel 2024 Healthcare Conference in New York teilnehmen, wo CEO Carmine Stengone um 16:10 Uhr ET präsentieren wird. Außerdem wird das Management an Einzelgesprächen auf der Jefferies 2024 London Healthcare Conference am 21. November teilnehmen. Die Präsentation von Stifel wird über einen Webcast auf der Website von Contineum verfügbar sein, mit Zugang zur Wiederholung.
- None.
- None.
-
Stifel 2024 Healthcare Conference, Monday, November 18, 2024,
New York - Carmine Stengone, Contineum’s President and CEO, will present at 4:10 p.m. ET. -
Jefferies 2024 London Healthcare Conference, Thursday, November 21, 2024,
London - Company management will participate in one-on-one meetings.
The Stifel presentation will be webcast on the Investors section of Contineum’s website. A webcast replay will also be available.
About Contineum Therapeutics
Contineum Therapeutics (Nasdaq: CTNM) is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Contineum is focused on targeting biological pathways associated with specific clinical impairments, that Contineum believes, once modulated, may demonstrably impact the course of disease. Contineum has a pipeline of internally-developed programs to address multiple NI&I disorders. Contineum has two drug candidates in clinical trials, PIPE-791, an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and progressive multiple sclerosis, and PIPE-307, a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis. PIPE-307 is being developed pursuant to a global license and development agreement between Contineum and Janssen Pharmaceutica NV, a Johnson & Johnson company, who has also announced plans to initiate a Phase 2 trial of PIPE-307 in depression in 2024. For more information, please visit www.contineum-tx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113433403/en/
Steve Kunszabo
Contineum Therapeutics
Senior Director, Investor Relations & Corporate Communications
858-649-1158
skunszabo@contineum-tx.com
Source: Contineum Therapeutics, Inc.
FAQ
When is Contineum Therapeutics (CTNM) presenting at the Stifel 2024 Healthcare Conference?
Which investor conferences will Contineum Therapeutics (CTNM) attend in November 2024?
Will Contineum Therapeutics' (CTNM) Stifel conference presentation be available online?
What type of meetings will Contineum (CTNM) conduct at the Jefferies 2024 London Healthcare Conference?
